
Sign up to save your podcasts
Or


CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and will have solid tumor data later this year, while 2026 will be data rich for BI-1206.
By BiotechTV5
44 ratings
CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and will have solid tumor data later this year, while 2026 will be data rich for BI-1206.

30,626 Listeners

1,863 Listeners

1,085 Listeners

325 Listeners

6,059 Listeners

60 Listeners

9,840 Listeners

86 Listeners

34 Listeners

19 Listeners

260 Listeners

497 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners